Eight hours into his testimony at the Vioxx trial in Atlantic City, N.J., last week, the plaintiffs’ first witness got a jolt.
The judge interrupted Merck sales and marketing executive David Anstice and gave jurors a curative instruction: Merck could have issued a safety warning at any time after it learned of the painkiller’s cardiovascular risks in March 2000.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
